HP
Hanmi Pharmaceutical at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Hanmi Pharmaceutical brings 5 presentations to ObesityWeek 2026 in National Harbor. Its posters center on long-acting peptide drugs, including the myostatin inhibitor HM500197, which preserves muscle mass during weight loss alongside incretin therapy. Others test the GLP-1/GIP/glucagon triple agonist HM15275 against dyslipidemia and obesity-associated colorectal cancer.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
HP Hanmi Pharmaceutical Seoul, South Korea | |
Pharmaceutical company developing long-acting incretin drugs, including efpeglenatide and the triple agonist HM15275, plus muscle-preserving candidates. | Poster Sun Nov 15 2:30pm–3:30pm HM500197 Combination with Incretin-Based Therapy Preserves Skeletal Muscle Mass during Weight Loss Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm HM500197, a Long-Acting Peptide Based Myostatin Inhibitor, Improves Muscle Mass in Obese Mice Metabolism and integrative physiology Poster Mon Nov 16 2:30pm–3:30pm Efpeglenatide Attenuates Psoriasis in Both Obese and Lean Mice Chronic disease and obesity complications Poster Mon Nov 16 2:30pm–3:30pm HM15275, a GLP-1/GIP/Glucagon Triple Agonist, Shows Anti-tumor Efficacy in an Obesity-Associated CRC Chronic disease and obesity complications Poster Mon Nov 16 2:30pm–3:30pm Therapeutic Potential of HM15275, a Long-Acting GLP-1/GIP/Glucagon Triple Agonist, for Dyslipidemia Chronic disease and obesity complications |
Find decision makers at Hanmi Pharmaceutical
Tell us what you sell and we’ll find the people at Hanmi Pharmaceutical most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction